To improve patient centricity in clinical development, we need to move past ‘gut-feeling’ and towards a data-led approach
Clinical development has faced several years of disruption from recent global events, from the pandemic to the ongoing war in Ukraine and now a looming economic crisis. Given the scale of such events, it’s more important than ever to be able to accurately predict outcomes for clinical trials and minimize patient burden and R&D costs. This requires moving from a perception-led approach to a data-led approach. It means learning from the past and present by simulating the future. And designing smarter trials that lead to faster cures.
Enabling Patient Centricity by Improving Diversity in Clinical Development
Our founder and CEO, Dr Gen Li was recently invited for a discussion with Xtelligent Healthcare Media, to explore our recent data around diversity in clinical trials. The conversation raised some interesting questions about diversity and decentralization in clinical trials. We’ve been reflecting on the issues raised in the discussion, and the strategies the clinical development industry can take to ensure patients who are enrolled in trials are representative of the patients who will receive the drug in the real-world.
Bigger Patient Data, Better Results for Clients
This week we reached an important milestone with our collaborative partner Sensyne Health, achieving an anonymized dataset of over 60 million patients. Arming clients with data combining clinical research, clinical trial, and real-world patient records, we are now another step forward in reaching our goal to harness the power of real-time data to help clients accelerate the delivery of life-saving treatments to patients.